StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.01−0.09 (-8.18%)

Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%

Tvardi Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Tvardi Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.03M. For fiscal 2025 it was -$23.50M. The highest annual figure on record is $2.83M in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.50M–
FY2024Dec 31, 2024-$18.31M–
FY2023Dec 31, 2023-$92.08M–
FY2022Dec 31, 2022-$78.73M–
FY2021Dec 31, 2021-$60.09M–
FY2020Dec 31, 2020-$5.49M–
FY2019Dec 31, 2019-$109.23M–
FY2018Dec 31, 2018-$22.30M–
FY2017Dec 31, 2017-$54.83M–
FY2016Dec 31, 2016-$47.38M–
FY2015Dec 31, 2015-$21.48M–
FY2014Dec 31, 2014-$17.64M-723.6%
FY2013Dec 31, 2013$2.83M–
FY2012Dec 31, 2012-$6.03M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.23M–
Q1 FY2026Mar 31, 2026-$5.86M–
Q4 FY2025Dec 31, 2025-$5.69M–
Q3 FY2025Sep 30, 2025-$4.26M–
Q2 FY2025Jun 30, 2025-$5.87M-124.8%
Q1 FY2025Mar 31, 2025-$7.69M–
Q4 FY2024Dec 31, 2024-$4.83M–
Q3 FY2024Sep 30, 2024-$6.66M–
Q2 FY2024Jun 30, 2024$23.64M–
Q1 FY2024Mar 31, 2024-$30.45M–
Q4 FY2023Dec 31, 2023-$17.37M–
Q3 FY2023Sep 30, 2023-$19.65M–
Q2 FY2023Jun 30, 2023-$20.45M–
Q1 FY2023Mar 31, 2023-$34.62M–
Q4 FY2022Dec 31, 2022-$23.51M–
Q3 FY2022Sep 30, 2022-$25.19M–
Q2 FY2022Jun 30, 2022-$4.50M–
Q1 FY2022Mar 31, 2022-$25.53M–
Q4 FY2021Dec 31, 2021-$1.25M-101.5%
Q3 FY2021Sep 30, 2021-$14.12M–
Q2 FY2021Jun 30, 2021-$21.01M–
Q1 FY2021Mar 31, 2021-$23.72M–
Q4 FY2020Dec 31, 2020$82.09M–
Q3 FY2020Sep 30, 2020-$21.62M–
Q2 FY2020Jun 30, 2020-$27.65M–
Q1 FY2020Mar 31, 2020-$38.30M–
Q4 FY2019Dec 31, 2019-$31.17M–
Q3 FY2019Sep 30, 2019-$25.64M–
Q2 FY2019Jun 30, 2019-$24.90M-160.7%
Q1 FY2019Mar 31, 2019-$27.53M–
Q4 FY2018Dec 31, 2018-$24.36M–
Q3 FY2018Sep 30, 2018-$20.49M–
Q2 FY2018Jun 30, 2018$41.02M–
Q1 FY2018Mar 31, 2018-$18.47M–
Q4 FY2017Dec 31, 2017-$11.41M–
Q3 FY2017Sep 30, 2017-$9.85M–
Q2 FY2017Jun 30, 2017-$11.93M–
Q1 FY2017Mar 31, 2017-$21.64M–
Q4 FY2016Dec 31, 2016-$13.19M–
Q3 FY2016Sep 30, 2016-$12.90M–

More Tvardi Therapeutics figures

See a number that looks wrong?